8-K filing — NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Filed: 2026-09-10 AccNo: 0001829126-26-009977 Size: 891 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-09-10 AccNo: 0001829126-26-009977 Size: 891 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers,
BTIG analyst Thomas Shrader reiterates NeOnc Technologies Hldgs (NASDAQ:NTHI) with a Buy and maintains $15 price target.